J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes
Executive Summary
Johnson & Johnson is taking steps to competitively position Procrit ahead of the changes to Medicare Part B reimbursement in 2005, Biopharmaceuticals Group Chairman Joe Scodari told investors July 13
You may also be interested in...
Aloxi Payment Cut By One-Third Under Medicare ASP Rule
MGI's anti-emetic Aloxi is among the products that will see the steepest payment cuts when the Centers for Medicare & Medicaid Services implements average sales price-based reimbursement for drugs covered by Medicare Part B in 2005
Aloxi Payment Cut By One-Third Under Medicare ASP Rule
MGI's anti-emetic Aloxi is among the products that will see the steepest payment cuts when the Centers for Medicare & Medicaid Services implements average sales price-based reimbursement for drugs covered by Medicare Part B in 2005
EPO Ceasefire? Amgen Aranesp Price To Remain Stable Unless J&J Acts First
Amgen does not intend to continue implementing Aranesp price discounts unless J&J moves first, Amgen Exec VP-Global Commercial Operations George Morrow said during an earnings call April 22